Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Regular Articles

Combined Targeted Inhibition of bcl-2, bcl-XL, Epidermal Growth Factor Receptor, and Protein Kinase A Type I Causes Potent Antitumor, Apoptotic, and Antiangiogenic Activity

Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, Roberta Caputo, Teresa Troiani, Bianca Maria Veneziani, Sabino De Placido, Angelo Raffaele Bianco, Uwe Zangemeister-Wittke and Fortunato Ciardiello
Giampaolo Tortora
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Caputo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincenzo Damiano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberta Caputo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Troiani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bianca Maria Veneziani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabino De Placido
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelo Raffaele Bianco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Zangemeister-Wittke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fortunato Ciardiello
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published February 2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: February 2003 to April 2021

AbstractFull-text HTMLPDF
Total192238202561

Cited By

Article Information

Volume 9, Issue 2, pp. 866-871

PubMed 
12576461

Published By 
American Association for Cancer Research
Print ISSN 
1078-0432
Online ISSN 
1557-3265
History 
  • Received June 5, 2002
  • Revision received September 12, 2002
  • Accepted September 13, 2002
  • Published first February 1, 2003.

Copyright & Usage 
© 2003

Author Information

  1. Giampaolo Tortora1,
  2. Rosa Caputo,
  3. Vincenzo Damiano,
  4. Roberta Caputo,
  5. Teresa Troiani,
  6. Bianca Maria Veneziani,
  7. Sabino De Placido,
  8. Angelo Raffaele Bianco,
  9. Uwe Zangemeister-Wittke, and
  10. Fortunato Ciardiello
  1. Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica [G. T., Ros. C., V. D., Rob. C., T. T., S. D. P., A. R. B., F. C.] and Dipartimento di Biologia e Patologia Cellulare e Molecolare [B. M. V.], Università di Napoli Federico II, 80131 Napoli, Italy, and Division of Oncology, University Hospital Zurich, 8044 Zurich, Switzerland [U. Z-W.]
View Full Text
PreviousNext
Back to top
Clinical Cancer Research: 9 (2)
February 2003
Volume 9, Issue 2
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Combined Targeted Inhibition of bcl-2, bcl-XL, Epidermal Growth Factor Receptor, and Protein Kinase A Type I Causes Potent Antitumor, Apoptotic, and Antiangiogenic Activity
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Combined Targeted Inhibition of bcl-2, bcl-XL, Epidermal Growth Factor Receptor, and Protein Kinase A Type I Causes Potent Antitumor, Apoptotic, and Antiangiogenic Activity
Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, Roberta Caputo, Teresa Troiani, Bianca Maria Veneziani, Sabino De Placido, Angelo Raffaele Bianco, Uwe Zangemeister-Wittke and Fortunato Ciardiello
Clin Cancer Res February 1 2003 (9) (2) 866-871;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Combined Targeted Inhibition of bcl-2, bcl-XL, Epidermal Growth Factor Receptor, and Protein Kinase A Type I Causes Potent Antitumor, Apoptotic, and Antiangiogenic Activity
Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, Roberta Caputo, Teresa Troiani, Bianca Maria Veneziani, Sabino De Placido, Angelo Raffaele Bianco, Uwe Zangemeister-Wittke and Fortunato Ciardiello
Clin Cancer Res February 1 2003 (9) (2) 866-871;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Regular Articles

  • Antifolate Resistance in a HeLa Cell Line Associated With Impaired Transport Independent of the Reduced Folate Carrier
  • Selective Induction of Apoptosis with Proton Pump Inhibitor in Gastric Cancer Cells
  • Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer
Show more Regular Articles

Experimental Therapeutics, Preclinical Pharmacology

  • A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcomes Acquired Paclitaxel (Taxol) Resistance in Human Non–Small Cell Lung Cancer
  • Ring Finger Protein 43 as a New Target for Cancer Immunotherapy
  • ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy
Show more Experimental Therapeutics, Preclinical Pharmacology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement